MPLT
MapLight Therapeutics, Inc.Company with tickers: MPLT
CIK
1770069
CUSIP
56565P103
Shares Outstanding
42,436,326
Website
https://www.maplightrx.com
Investor Relations
https://maplightrx.com/investor-relations/
13F Activity (30d)
1 filings
1 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jonathan Gillis | interim Chief Financial Officer and interim principal financial officer | Appointed | 2026-06-18 |